Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Everest Organics begins manufacturing API for molnupiravir 

By Brian Buntz | October 12, 2021

Molnupiravir

Molnupiravir photo courtesy of Merck.

Bengaluru, India–based Everest Organics (BOM:524790) saw its share price jump 15% today to ₹347.10 after announcing it has begun manufacturing the active pharmaceutical ingredient (API) for a molnupiravir generic.

Molnupiravir is an experimental oral drug that appears to substantially reduce the rate of COVID-19-related hospitalization for patients with mild-to-moderate infections.

Reuters has reported that molnupiravir developer Merck (​​NYSE:MRK) has agreements with multiple Indian companies related to the manufacture of the drug.

Merck partnered with Ridgeback Biotherapeutics in developing molnupiravir, which scientists with ties to Emory University initially discovered.

“After the successful development and commercialization of various COVID-19 drugs, such as Oseltamivir, Remdesivir, [and] Posaconazole, Everest Organics Limited is on its path of expansion of this portfolio,” said Everest Organics CEO Srikakarlapudi Sirisha in a statement.

Everest notes that its Hyderabad facility exports APIs to drug companies in more than 40 countries.

Merck formally filed for emergency use authorization of the drug on Monday.


Filed Under: Drug Discovery, Infectious Disease
Tagged With: active pharmaceutical ingredient, API, covid-19, Everest Organics, Molnupiravir, Ridgeback Biotherapeutics
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50